What is the highest mg of Wegovy available in the UK?

Was 2.4 mg really the top of the Wegovy dose ladder?

Until recently, yes. For the first few years after Wegovy launched in the UK, the standard 2.4 mg weekly dose was the licensed ceiling. The five-step titration schedule (0.25 mg → 0.5 mg → 1.0 mg → 1.7 mg → 2.4 mg, with roughly four weeks at each level) was designed to let your body adjust to semaglutide's appetite-suppressing effects before settling at maintenance. That ceiling changed in January 2026 when the MHRA authorised a 7.2 mg maintenance dose. Initially it was reached by combining three 2.4 mg pens into a single weekly injection, an impractical arrangement. The cleaner solution came on 14 April 2026, when the MHRA approved a dedicated single-dose 7.2 mg pen: one pre-set weekly injection with a built-in covered needle that locks after use. You still start at 0.25 mg; the titration schedule is unchanged up to 2.4 mg, then continues by prescriber guidance to the new ceiling, and if you want a full breakdown of what the highest dose of Wegovy is and how it fits into the schedule, that page covers every step in detail. The MHRA's announcement on 14 April 2026 confirmed the 7.2 mg pen is licensed for adults with a BMI of 30 or above only, not for lower BMI thresholds or for the cardiovascular indication.

What do the trial results at 7.2 mg actually show?

The headline figure is roughly 20.7% average weight loss over 72 weeks at the 7.2 mg dose. That is a meaningful step up from the approximately 15% seen in STEP 1, the pivotal 2.4 mg trial published in the New England Journal of Medicine, and it narrows the gap with tirzepatide's results at its highest dose, a comparison discussed openly in NICE's appraisal of both medicines. None of this means everyone using Wegovy will reach 20%, and clinical trial conditions (diet coaching, close monitoring, high adherence) rarely replicate daily life precisely. The right way to read these figures is as a realistic ceiling for a motivated patient on the highest dose, not as a personal forecast. For a closer look at how individual dose steps compare and what to expect at each stage, the Wegovy doses overview covers the evidence across the full schedule. Results at any level also depend on sustained lifestyle changes alongside the medicine; Wegovy is licensed as an adjunct to a reduced-calorie diet and increased physical activity, not a standalone treatment.

Who can actually reach the 7.2 mg dose?

The 7.2 mg pen is licensed for adults with a BMI of 30 or above. That is a narrower eligibility than the injection's general licence, which also covers BMI 27–29.9 alongside a weight-related condition such as high blood pressure, type 2 diabetes or obstructive sleep apnoea. Reaching 7.2 mg also requires tolerance of the lower doses first. A prescriber will assess whether titration to the maximum is appropriate based on your response, your side-effect history and your overall clinical picture, it is not automatic simply because 7.2 mg now exists. Most people experience Wegovy's most pronounced gastrointestinal side effects (nausea, loose stools, indigestion) in the first weeks at each new dose level, and these typically settle within a week or two. A slower titration pace is an option if side effects are significant. The NHS notes that if fewer than 5% of body weight is lost after six months at the highest tolerated dose, continuing treatment should be reviewed. For context on how private access works alongside the NHS route, the highest dose for weight loss page covers the clinical criteria in more detail. Suitability is always a clinical decision, made by a prescriber who reviews your full medical history, not a number on a BMI chart alone.

What actually arrives if you're prescribed the 7.2 mg pen?

The 7.2 mg Wegovy pen is a pre-filled, single-dose device with an auto-dosing mechanism and a covered needle that locks automatically after use, no manual dialling required. It arrives, like all medicines dispatched by our pharmacy, in plain unbranded packaging via DPD with a tracking notification to your phone. The pen itself needs refrigerating at 2–8°C until use, with a limited window at room temperature as detailed in the patient information leaflet; always follow the leaflet rather than any general guidance you've read online, since storage windows can differ between pen formats. The 7.2 mg pen is distinct from the earlier 2.4 mg pens, so if you have been on Wegovy before, what you receive will look and feel different. Specific dose and pen availability is confirmed at consultation, since stock and prescribing decisions depend on your clinical assessment. If you'd like to understand more about Wegovy as a treatment before starting, the weight-loss treatment overview is a useful starting point, and you can explore how private Wegovy prescriptions work in the UK in more detail. Wegovy is a prescription-only medicine; any reputable source will require a proper clinical assessment before dispensing it. You can verify any online pharmacy against the GPhC register at pharmacyregulation.org/registers before sharing any health information. When you're ready to discuss whether Wegovy and the right dose for you, speak to our prescribers through a free consultation.